By Anthony O. Goriainoff
IQ-AI said the results of a recent study validate the use of the reduced-dose gadolinium-based contrast agent on magnetic resonance imaging scanners.
The U.K. medical-software and services company said Friday that the study--which was undertaken by its imaging biometrics subsidiary--provided an immediate option for cutting GBCA by 50% on 1.5T and 3T MRI scanners.
"The study demonstrates that a single dose, no preload, low flip angle method doesn't compromise image quality. This is a great added benefit for patients who may have concerns about GBCA risks, and for administrators looking for opportunities to curtail operational expenses," the company said.
Shares at 0713 GMT were up 0.35 pence, or 8.8%, at 4.35 pence.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
